The effects of platelet activating factor antagonist, TCV309, on the relationship between electrophysiological and mechanical status during myocardial ischemia and reperfusion.
Tamura
K
K
Second Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
Kimura
Y
Y
Tamura
T
T
Kitashiro
S
S
Izuoka
T
T
Iwasaka
T
T
Inada
M
M
D000200:Action Potentials; D000818:Animals; D004285:Dogs; D004594:Electrophysiology; D006439:Hemodynamics / Q000187:drug effects; D007546:Isoquinolines / Q000494:pharmacology*; D009200:Myocardial Contraction / Q000187:drug effects; D017202:Myocardial Ischemia / Q000503:physiopathology*; D015428:Myocardial Reperfusion Injury / Q000503:physiopathology*; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors*; D011726:Pyridinium Compounds / Q000494:pharmacology*; D044005:Tetrahydroisoquinolines
D007546:Isoquinolines; D010972:Platelet Activating Factor; D011726:Pyridinium Compounds; D044005:Tetrahydroisoquinolines; C067430:TCV 309